期刊文献+

磷酸奥司他韦胶囊与其他抗病毒药物治疗上呼吸道病毒感染疗效对比 被引量:9

Comparison of the Effect of Oseltamivir Phosphate Capsules and Other Antiviral Drugs for the Treatment of Upper Respiratory Tract Infection
下载PDF
导出
摘要 目的:探讨比较磷酸奥司他韦胶囊与其他抗病毒药物治疗上呼吸道病毒感染的临床疗效。方法:本次入选患者为2014年11月至2016年5月来我院发热门诊就诊的上呼吸道感染患者150例,根据随机数学法进行分组,对照组75例,观察组75例,对照组患者给予利巴韦林注射液注射,同时给予维C银翘片口服;观察组患者给予磷酸奥司他韦胶囊口服。观察并记录两组患者的平均退热时间、症状改善时间、治愈时间,并对治疗效果进行评价。结果:观察组患者的平均退热时间、症状改善时间和治愈时间均显著少于对照组(P<0.05)。两组患者经过治疗后,观察组总有效率显著高于对照组(98.7%vs.82.7%,P<0.05)。结论:对于上呼吸道病毒感染的患者给予磷酸奥司他韦胶囊,可有效缩短患者临床症状改善时间,减轻患者痛苦,提高临床治疗效果,值得在临床推广应用。 Objective : To investigate the clinical curative effect of oseltamivir phosphate capsules and other antiviral drugs for the treatment of upper respiratory tract infection. Methods : The 150 patients with upper respiratory tract infection from November 2014 to May 2016 of fever clinic in our hospital, were divided randomly into two groups. 75 cases were in the control group and 75 cases were in the observation group. Patients in the control group were treated with ribavirin injection and vitamin C yinqiao Tablets. Patients in the observation group were treated with oral administration of oseltamivir phosphate capsules. The average time of fever patients, the time of symptoms improvement, healing time and the effect of treatment were compared between two groups. Results : The average defervescence time, the time of symptoms improvement and cure time were less than those of the control group(P〈0.05). Two groups of patients after treatment, the observation group of 75 patients, 53 cases were markedly effective,21 cases effective, 1 cases ineffective, the total effective 74 cases, the total efficiency in the observation group was significantly higher than that of the control group(98.7% vs 82.7%, P〈0.05). Conclusion : Oseltamivir phosphate capsules for the patients with upper respiratory tract infection can effectively shorten the time of the clinical symptoms improvement, reduce the pain of patients, improve the clinical treatment effect. It is worthy of popularizing in clinic.
作者 杨赤 张月红
出处 《岭南急诊医学杂志》 2016年第5期492-493,496,共3页 Lingnan Journal of Emergency Medicine
关键词 磷酸奥司他韦胶囊 利巴韦林 上呼吸道病毒感染 oseltamivir phosphate capsules ribavirin upper respiratory tract virus infection
  • 相关文献

参考文献5

二级参考文献31

  • 1邓伟吾,李庆云,钟南山.流感季节磷酸奥司他韦治疗临床诊断的流感疑似患者的疗效与安全性研究[J].中华医学杂志,2004,84(24):2132-2136. 被引量:40
  • 2呼守舫.痰热清注射液治疗流行性腮腺炎疗效观察[J].中华临床医学杂志,2005,6(5):90-90. 被引量:3
  • 3陈晓红,祝亚非,关山越,姚骏骅,任三香,张倩芝.抗流感药物奥司他韦的结构确证[J].广州化工,2006,34(6):34-35. 被引量:2
  • 4Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA, 2003, 289:179-186.
  • 5Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and osehamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res, 2005, 68:43-48.
  • 6Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med, 2005, 353:1363-1373.
  • 7Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med, 1999, 341:1336-1343.
  • 8WHO. Advice on use of oseltamivir, http://www, who. int/ csr/disease/avian _ influenza/guidelines/oseltamivir, available on Mar. 17, 2006.
  • 9Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother, 2006, 50: 2395-2402.
  • 10Leneva IA, Roberts N, Govorkova EA, et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/ 1074/99 (HgN2) influenza viruses. Antiviral Res, 2000, 48: 101-115.

共引文献23

同被引文献90

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部